Titan Pharmaceuticals Announces Reverse Stock Split and Ratio
- None.
- None.
The announcement of Titan Pharmaceuticals' 1-for-20 reverse stock split is a strategic move that aims to consolidate shares and potentially elevate the market price per share. This action often indicates an attempt to comply with Nasdaq's minimum bid price requirements and avoid delisting. It's crucial to assess the liquidity implications, as the reduced number of shares could affect the stock's trading volume.
Investors should consider the psychological impact of such a move. While it does not fundamentally alter the company's valuation, it can influence investor perception. Historical data suggests mixed outcomes for companies executing reverse splits, with success contingent on underlying financial health and market conditions.
It is also pertinent to monitor the post-split behavior of the stock. Companies that demonstrate improved financial performance and growth prospects post-reverse split might see sustained investor interest, whereas those that don't could experience further price declines.
From a market research perspective, the reverse stock split by Titan Pharmaceuticals reflects a strategic decision that could be a precursor to future corporate actions, such as raising additional capital. The market often views reverse splits with skepticism, associating them with companies in distress. However, it can also be a step towards restructuring efforts aimed at revitalizing the company's market standing.
Analyzing the sector-specific trends, biopharmaceutical companies like Titan often face volatile markets due to the high risk and reward nature of their products. The company's ability to navigate the post-split market will depend on its pipeline's potential and the industry's competitive landscape.
Stakeholders should assess the company's long-term strategic plans and how this reverse split aligns with those. A clear, forward-looking strategy could reassure investors and mitigate the initial negative sentiment that can accompany such announcements.
The reverse stock split is a regulatory maneuver that impacts Titan Pharmaceuticals' compliance with stock exchange listing standards. The Nasdaq Capital Market, for instance, has minimum bid price requirements that companies must meet to maintain their listing. Reverse splits can be a tool to meet such criteria.
For shareholders, understanding the proportional adjustments to options and warrants is crucial. These adjustments will maintain the economic value of these derivatives, but the liquidity and marketability may be influenced by the new share structure.
It's also important to note that while the reverse split does not inherently change the company's market capitalization, it does alter the number of shares outstanding, which can affect the earnings per share (EPS) metric, a key indicator watched by analysts and investors.
SOUTH SAN FRANCISCO, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company's common stock, which will be effective following the filing of an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”). The Company's stockholders approved the reverse stock split at a Special Meeting of Stockholders on December 27, 2023. The Company’s shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market following the filing of the Amendment, which is intended go effective on January 9, 2024.
As a result of the reverse split, each 20 shares of the Company's issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock, par value
Immediately after the reverse split becomes effective, there will be approximately 781,503 shares of common stock issued and outstanding. The common shares will trade under a new CUSIP number, 888314705, and continue to trade under the symbol “TTNP.” All stock options and warrants of the Company outstanding immediately prior to the reverse stock split will be proportionally adjusted.
The Company has appointed its transfer agent, Continental Stock Transfer & Trust Company (“Continental”), to act as exchange agent for the reverse stock split. Stockholders owning shares via a bank, broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split and will not be required to take further action in connection with the reverse stock split, subject to brokers' particular processes. Continental can be reached at (212) 509-4000.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), based in South San Francisco, CA, is a development stage company developing proprietary therapeutics utilizing ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. In December 2021, Titan commenced a process to explore and evaluate strategic alternatives to enhance shareholder value.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. A complete discussion of the risks and uncertainties that may affect Schmitt's business, including the business of its subsidiary, is included in “Risk Factors” in the Company's most recent Annual Report on Form 10-K as filed by the Company with the Securities and Exchange Commission.
Media & Investor Contacts:
Kate Beebe DeVarney, Ph.D.
President and Chief Operating Officer
(650) 989-2258
FAQ
What is the recent announcement from Titan Pharmaceuticals, Inc. (NASDAQ: TTNP)?
When will the reverse stock split of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) be effective?
How many shares of common stock will be issued and outstanding after the reverse stock split for Titan Pharmaceuticals, Inc. (NASDAQ: TTNP)?
Will the common shares of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) continue to trade under the same symbol after the reverse stock split?
Who has been appointed as the exchange agent for the reverse stock split of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP)?
